Fulgent Genetics to Participate in the H.C. Wainwright BIOCONNECT 2021 Conference
January 06 2021 - 08:00AM
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the
“company”), a technology company providing comprehensive testing
solutions through its scalable technology platform, today announced
that its Chief Financial Officer Paul Kim, and Chief Commercial
Officer Brandon Perthuis are scheduled to virtually participate in
a presentation at the H.C. Wainwright BIOCONNECT 2021 Conference
taking place January 11 to 14, 2021.
A webcast of the presentation will be available beginning
at 6:00 a.m. ET on January 11, 2021 on the Investor Relations
section of the Fulgent Genetics website at ir.fulgentgenetics.com,
and will be available for 90 days following the conference.
About Fulgent Genetics
Fulgent Genetics’ proprietary technology platform has created a
broad, flexible test menu and the ability to continually expand and
improve its proprietary genetic reference library while maintaining
accessible pricing, high accuracy and competitive turnaround times.
Combining next generation sequencing (“NGS”) with its technology
platform, the Company performs full-gene sequencing with
deletion/duplication analysis in an array of panels that can be
tailored to meet specific customer needs. In 2019, the Company
launched its first patient-initiated product, Picture Genetics, a
new line of at-home screening tests that combines the Company’s
advanced NGS solutions with actionable results and genetic
counseling options for individuals. Since March 2020, the Company
has commercially launched several tests for the detection of
SARS-CoV-2, the virus that causes the novel coronavirus
(“COVID-19”), including NGS and reverse transcription polymerase
chain reaction (“RT-PCR”) - based tests. The Company has received
Emergency Use Authorization (“EUA”) from the U.S. Food and Drug
Administration (“FDA”) for the RT-PCR-based tests for the detection
of SARS-CoV-2 using upper respiratory specimens (nasal,
nasopharyngeal, and oropharyngeal swabs) and for the at-home
testing service through Picture Genetics. A cornerstone of the
Company’s business is its ability to provide expansive options and
flexibility for all clients’ unique testing needs through a
comprehensive technology offering including cloud computing,
pipeline services, record management, web portal services, clinical
workflow, sequencing as a service and automated lab services.
Investor Relations Contacts:The Blueshirt
GroupNicole Borsje, 415-217-2633; nicole@blueshirtgroup.com
Fulgent Genetics (NASDAQ:FLGT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Fulgent Genetics (NASDAQ:FLGT)
Historical Stock Chart
From Mar 2023 to Mar 2024